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Abstract 
Background.  Radiotherapy after breast conserving surgery increases local control.  Standard 
radiotherapy includes whole breast irradiation delivered in a daily fashion over 5 or 5½ weeks. 
All patients may not require entire breast treatment.  We tested the feasibility of limited surgery 
with limited irradiation using interstitial brachytherapy to the tumor bed in a selected group of 
patients with stage I breast cancer in a phase II trial.   
Methods.  Women aged 55 years or older with low or intermediate grade stage I tumors were 
treated with placement of interstitial catheters at the time of lumpectomy and axillary node 
dissection. The tumor bed was treated peri-operatively, using either low-dose-rate or high-dose-
rate brachytherapy with Iridium-192 to deliver 16 to 25 Gy to the tumor bed over one to two 
days. 
Results.  Ninety-five breasts (94 women) were treated on the protocol.  There were four (4%) 
local recurrences in the breast at a median follow-up interval of 66 months (range, 2.8 - 152). 
Cosmetic appearance ranged between good to excellent.  There were no long-term radiation 
related complications. 
Conclusions. In a selected group of patients, lumpectomy and immediate peri-operative low-
dose interstitial brachytherapy to the tumor bed yielded local control equivalent, without 
significant morbidity, to that observed in a historical series of whole breast irradiation.   
KJM 2009; 2(2):33-40. 
 
Introduction 
Several randomized trials clearly have 
established that breast conservation therapy 
with irradiation and mastectomy have 
equivalent survival results for early stage 
breast cancer.1-6  The standard of care for 
breast conservation therapy includes whole 
breast irradiation. Over the last decade, there 
has been increasing interest in the feasibility 
of doing partial breast irradiation in selected 
cases with interstitial brachytherapy7-13, 
external beam therapy14,15, or intra-operative 
radiotherapy.16,17  The rationale for reducing  
 
 
 
the volume of breast irradiated includes 
improved cosmesis, improved function, 
greater convenience for patients, reduced 
radiation dose, and decreased risk of second 
malignancy.  
At our institution, we initiated a single 
arm Phase II trial in June 1993 to assess the 
efficacy of a low dose of tumor bed brachy-
therapy immediately following lumpectomy 
in a selected subset of patients with invasive 
breast cancer.18 This report represents an 
update of our continued accrual into this 
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trial including a larger number of patients 
and a longer period of follow-up. 
 
Methods 
Study procedures, including obtaining 
informed consent, were conducted in accord 
with the ethical standards of the institution’s 
Human Subjects Committee. The trial was 
initiated in June 1993. For enrollment in the 
study, prospective subjects were required to 
meet all four of the following criteria: 
patient age > 60 years, tumor size < 2 cm, 
low or intermediate histologic grade, and 
pathologically negative axillary nodes. 
Subsequently, the study was modified to 
include patients > 55 years of age based on 
the finding that local recurrence rate in 
women over 55 years with quadrantectomy 
was not significantly different from those 
who received immediate breast irradiation.19  
The requirement for pathologically 
negative axillary lymph nodes was modified 
to include clinically negative nodes in 
tumors < 1 cm, if an axillary lymph node 
dissection was deemed medically inap-
propriate by the treating surgeon.  However, 
with the advent of sentinel lymph nodal 
sampling, this procedure replaced axillary 
lymph node dissection. Tumors with the 
following histologic types made a patient 
ineligible for the protocol: infiltrating ductal 
carcinoma with extensive intraductal 
component, pleomorphic type of infiltrating 
lobular carcinoma, ductal carcinoma in situ, 
or lobular carcinoma in situ.   
The primary outcome of the trial was to 
assess the rate of local recurrence with 
limited radiotherapy.  The stopping rule 
specified that the study would be stopped if 
the local recurrence rate was higher than the 
local recurrence rate obtained at our 
institution in operable breast cancer treated 
with the conventional approach of breast 
conservation therapy plus brachytherapy to 
the tumor site and entire breast irradiation.  
The recurrence rate at a median follow-up of 
69 months in our series was 14 of 250 
breasts or 5.6%.20 
Pathologic diagnoses were established 
by either excisional, incisional, mammotest 
core biopsies, or fine needle aspiration 
biopsies.  Patient eligibility was determined 
based upon the previously outlined criteria.  
Eligible patients were advised about the 
option of partial breast irradiation following 
lumpectomy utilizing peri-operative brachy-
therapy and informed consent was obtained.   
Margin status of the wide excision 
specimens was evaluated by frozen section 
examination.  Patients with clear margins of 
invasive or intraductal carcinoma underwent 
placement of interstitial catheters into the 
tumor bed by the technique described in our 
previous papers.21,22  Patients were treated 
with low-dose-rate brachytherapy (LDRB) 
between December 1993 and June 1999, 
when the new technique of high-dose-rate 
brachytherapy (HDRB) became routinely 
available. Subsequently, all patients were 
treated using HDRB.  
Prior to July 1999, axillary node 
dissections were performed and a final 
pathologic evaluation was obtained within 
24 hours from the time of surgery. 
Subsequently, when sentinel lymph node 
sampling became the standard, a frozen 
section examination of the nodes was 
performed and node negative patients were 
treated according to the protocol.  If the final 
pathology report revealed positive nodes, the 
patient was deemed ineligible for the 
protocol of brachytherapy alone and in 
addition received whole breast irradiation. 
After the operation, simulation films 
were performed for localization of the 
catheters in the tumor bed and computation 
of isodose curves was carried out in the 
Department of Radiation Oncology.  In 
those treated with LDRB, the catheters were 
after-loaded with low-dose-rate Iridium-192, 
varying in strength between 0.33 and 0.44 
mg radium equivalent. A 20 to 25 Gy dose 
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was delivered to an isodose line that 
encompassed all the iridium ribbons and was 
at least one cm deep to the tumor bed over 
24 to 48 hours.   
In HDRB cases, a biological equivalent 
dose (BED) of 16 to 22 Gy was delivered in 
four fractions. Not all the patients received 
adjuvant systemic therapy; some patients 
were not recommended treatment and others 
refused    treatment.     Forty-eight    patients 
received hormonal treatment, either 
tamoxifen or anastrozole. Three patients 
received adjuvant chemotherapy. The 
patients were followed on a regular basis 
and regular mammograms were obtained. 
 
Results 
A total of 94 post-menopausal patients 
enrolled in the protocol between December 
1993 and November 2005.  One African-
American patient in her 60’s had bilateral 
breast cancer with diagnoses one year apart 
and each breast was treated to the tumor bed 
with brachytherapy.  Patient demographics 
are outlined in Table 1. Tumor 
characteristics are outlined in Table 2. 
Tumors ranged in size from a largest 
dimension of 0.3 cm to 2.0 cm, with a 
median of 1.0 cm.  Sixty-five of 95 tumors 
were as expected, of the invasive ductal 
carcinoma type, not otherwise specified 
(Table 3).  The treatment details are 
provided in Table 4.   
Median time of follow-up was 69 months 
with a range of three to 152 months.  Eighty 
of the 94 patients (85%) were alive in 2008, 
78 (83%) with no evidence of disease and 
two (2%) with evidence of distant disease.  
Of the 14 deaths, there was evidence of 
breast cancer (distant disease but no local 
recurrence) at time of death for 10 of the 
women.  Of the 95 breasts treated, a local 
recurrence occurred in only four women 
(4%; Figure 1) who were subsequently 
treated  with  mastectomy   or  whole  breast  
 Table 1.  Demographics of 94 women 
treated on the protocol. 
 
Table 2.  Characteristics of 95 tumors at 
diagnosis. 
 
irradiation (Table 5).  With only four events, 
it would not be possible to identify potential 
prognostic factors for recurrence with any 
statistical power. All four patients were alive 
Demographics  Number 
of 
Patients 
Percent 
Age at Diagnosis, 
years 
  
55-59 11 12 
60-69 34 36 
70-79 39 41 
80-89 8 9 
91-100 2 2 
Race   
African-American 12 13 
Caucasian 82 87 
Tumor 
Characteristics 
Number 
of 
Tumors 
Percent 
Detection   
Mammographic 
findings alone 
74 78 
Palpable 19 20 
Bloody nipple 
discharge 
2 2 
Laterality   
Left 45 47 
Right 50 53 
Site of primary   
Upper outer quadrant 54 57 
Upper inner quadrant 19 20 
Lower outer 
quadrant 
4 4 
Lower inner 
quadrant 
6 6 
Central  1 1 
Contiguous 11 12 
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Table 3.  Pathologic characteristics of 95 tumors. 
  *Tumor grade is based on the Elston and Ellis modification of the Bloom and Richardson’s 
grading system.24 
**Estrogen receptor status is determined by immunohistochemical analysis with expression of 
>10% nuclear staining considered positive.   
 
 
Table 4.  Treatment characteristics of 95 tumors. 
 
 
Pathologic Characteristics Number of Tumors Percent 
Histology   
Invasive ductal carcinoma, NOS 65 68 
Invasive tubular carcinoma 5 5 
Invasive colloid (mucinous) carcinoma 7 7 
Invasive lobular 12 13 
Mixed invasive ductal and lobular 6 6 
T1 Categories   
T1mic 1 1 
T1a 10 11 
T1b 38 40 
T1c 46 48 
Histological Grade*   
Grade 1 59 62 
Grade 2 36 38 
Estrogen Receptor Status**   
Positive 79 83 
Negative 6 6 
Unknown 10 11 
Treatment Number of Tumors Percent 
Axillary Procedure   
None 7 7 
Level I dissection 1 1 
Sentinel node sampling 54 57 
Axillary node dissection 33 35 
Brachytherapy   
LDRB; BED = 20 – 25 Gy 27 28 
HDRB; BED = 14 – 22 Gy 68 72 
Systemic Treatment    
None 44 46 
Anti-hormone therapy 48 51 
Chemotherapy 3 3 
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Figure 1. Freedom from local recurrence of the affected breast (n=95) as a function of time after 
diagnosis. 
 
Table 5.  Local tumor recurrence in four patients. 
Interval from 
Diagnosis  
(in months) 
Quadrant Initial 
Treatment 
Treatment of 
Recurrence 
Status 
32 Different HDRB 
22 Gy 
Whole Breast 
Radiotherapy 
NED* 
57 months 
43 Same HDRB 
16 Gy 
Mastectomy NED 
13 months 
48 Different HDRB 
22 Gy 
Whole Breast 
Radiotherapy 
NED 
43 months 
93 Same LDRB 
20 Gy 
Mastectomy NED 
25 months 
*NED: No evidence of disease. 
 
at last follow-up, ranging from 13 to 57 
months after time of recurrence.  Cosmetic 
appearance of the breast, judged according 
to our criteria,23 was deemed to be good to 
excellent in all patients.  Radiation-related 
complications were evaluated during follow-
up and no long-term sequelae were 
observed.  
Discussion 
Several randomized studies have 
established the validity of breast 
conservation surgery followed by irradiation 
in early stage breast cancer.1-6  The National 
Surgical Adjuvant Breast and Bowel Project  
(NSABP) B-06 clearly demonstrated that 
omission of radiotherapy leads to an 
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unacceptably high local recurrence rate.5 
Other trials have attempted to identify 
subsets of patients who could be at a low 
risk for breast relapse without breast 
irradiation.25-27  In each such trial, the local 
recurrence rate without irradiation was 
significantly higher than with irradiation. 
Pathological analysis of local breast 
recurrences following lumpectomy in the 
NSABP  B-06  trial determined 86% of local 
recurrences to be in the same quadrant as the  
initial primary.28  Gump et al.29 noted 90% 
of multicentric foci in 657 mastectomy 
specimens to be in close proximity to the 
primary.  Similarly, Holland et al.30 
determined that in 43% of 282 invasive 
cancers tumor foci were present within two 
cm from the reference tumor. 
A viable compromise between full-scale 
radiation and no radiation would be 
radiation restricted to the tumor bed. There 
are several such trials published in this 
respect.  The doses of radiation to the tumor 
bed have varied among the different 
investigators from 30 to 55 Gy.  The results 
of the current on-going NSABP protocol 
which randomized patients with tumors less 
than three cm to tumor bed irradiation 
versus whole breast irradiation would 
probably     standardize     radiotherapy      in  
particular subsets of women who desire 
breast conservation therapy. 
When we initiated our phase II trial, we 
decided on a dose of 20 to 25 Gy to the 
tumor bed with LDRB on a very 
conservative principle. Our previous work 
had revealed that peri-operative irradiation 
to tumor bed, accomplished by placement of 
implant catheters under direct visualization, 
enhanced local control.20-22,31,32 The dose 
was prescribed to the periphery of tumor 
bed. The center of the tumor bed would 
receive at least 150% of the dose (i.e., 30 to 
37.5 Gy) which yielded a radiobiological 
equivalent of approximately 40 to 45 Gy of 
external beam radiation given at 1.8 Gy per 
fraction.33,34   
When we replaced LDRB with HDRB, 
equivalent doses were calculated and 
delivered in four fractions to facilitate 
delivery within two days of surgical 
excision.  Further, if any of our patients 
suffered a recurrence in the breast, at that 
point, wide excision with external beam 
radiotherapy to the entire breast could still 
be offered as an option versus a mastectomy, 
without risk of tissue necrosis or rib 
fractures.  If the recurrence happened to be 
in another quadrant, an interstitial boost to 
the tumor bed in addition could be offered. 
In summary, the results presented in this 
study supported our original preliminary 
review.18 Our local recurrence rate at 66 
months was 4%, which was comparable to 
results reported by other investigators.7-13  In 
addition, this rate was lower than the 5.6% 
obtained in our series with standard 
radiotherapy.20 The doses used in our trial 
were lower than those used by other 
investigators.7-13  However, our trial was in a 
selected group of patients, who were 55 or 
older, with stage I tumors with low or 
intermediate grade.  
Our results may be due to the close 
collaboration between the surgeon and 
radiation oncologist, meticulous attention to 
margins, placement of interstitial catheters 
into the open surgical bed under direct 
visualization, generous coverage of the 
tumor cavity, and the biological advantage 
of immediate (within 24 to 48 hours of 
surgery) brachytherapy to the tumor bed.   
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